1. Scrip
  2. >>Business
  3. >>Earnings

AbbVie’s Gonzalez Outlines CEO Succession Process

Humira Erosion Follows Projections

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

AbbVie may look to an internal successor to Rick Gonzalez once he is satisfied the company is back on a growth trajectory. Skyrizi and Rinvoq continue meteoric growth, with increased sales projections.

AbbVie Building
AbbVie outlined its succession strategy for CEO Rick Gonzalez • Source: Shutterstock (Valeriya Zankovych/Shutterstock)

With AbbVie Inc. not quite a year into US biosimilar competition to top-seller Humira, some shareholders’ thoughts apparently are turning to what is next for the large pharma, especially since the revenue paths for Humira post-US patent expiration and its successors Skyrizi and Rinvoq are in line or better than what was expected. Chairman and CEO Rick Gonzalez discussed succession plans for the top spot during AbbVie’s fourth quarter and full year 2023 sales and earnings call on 2 February.

Previously, Gonzalez had said he would recommend transitioning to his successor once AbbVie had navigated through the worst of Humira’s...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.